Scholarlink

<p>Data from the placebo arm of DEN-301, a phase 3 trial of the TAK-003 dengue vaccine, were evaluated in this secondary post hoc analysis to assess dengue burden. Participants were aged 4–16 years from Asia Pacific and Latin America. The primary endpoint was efficacy of TAK-003 against virologically confirmed dengue (VCD). Hospitalized VCD was a secondary endpoint. Active surveillance captured both hospitalized and non-hospitalized cases. Among 6,687 placebo participants (30,620.6 person-years (p-y)), 9,698 febrile illnesses (incidence rate (IR) 31.7 per 100 p-y) occurred; 5.8% (<i>n</i> = 560) were dengue. Most were DENV-1 (41.1%) or DENV-2 (34.5%). Dengue incidence differed between Asia Pacific (IR 2.7 per 100 p-y) and Latin America (IR 1.2 per 100 p-y). A total of 19 participants had dengue haemorrhagic fever or severe dengue. Of the VCD cases, 25.4% (142/560) were hospitalized. Here we highlight geographic, age-specific and temporal differences in dengue disease, underscoring the need for adaptive public health strategies to effectively control the disease (ClinicalTrials.gov identifier: <a href="https://clinicaltrials.gov/study/NCT02747927">NCT02747927</a>).</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Burden of dengue in children in eight endemic countries in Asia and Latin America: a secondary analysis of the DEN-301 trial

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年7月8日

查看全文
  • Randee Kastner,
  • Eduardo López-Medina,
  • Chukiat Sirivichayakul,
  • Shibadas Biswal,
  • Ian Escudero,
  • Nicolas Folschweiller,
  • Nicholas Roubinis,
  • Vianney Tricou,
  • Suely Tuboi,
  • John Weil

摘要

Data from the placebo arm of DEN-301, a phase 3 trial of the TAK-003 dengue vaccine, were evaluated in this secondary post hoc analysis to assess dengue burden. Participants were aged 4–16 years from Asia Pacific and Latin America. The primary endpoint was efficacy of TAK-003 against virologically confirmed dengue (VCD). Hospitalized VCD was a secondary endpoint. Active surveillance captured both hospitalized and non-hospitalized cases. Among 6,687 placebo participants (30,620.6 person-years (p-y)), 9,698 febrile illnesses (incidence rate (IR) 31.7 per 100 p-y) occurred; 5.8% (n = 560) were dengue. Most were DENV-1 (41.1%) or DENV-2 (34.5%). Dengue incidence differed between Asia Pacific (IR 2.7 per 100 p-y) and Latin America (IR 1.2 per 100 p-y). A total of 19 participants had dengue haemorrhagic fever or severe dengue. Of the VCD cases, 25.4% (142/560) were hospitalized. Here we highlight geographic, age-specific and temporal differences in dengue disease, underscoring the need for adaptive public health strategies to effectively control the disease (ClinicalTrials.gov identifier: NCT02747927).